SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-066060
Filing Date
2022-03-04
Accepted
2022-03-04 16:06:02
Documents
12
Period of Report
2022-02-28
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d278002d8k.htm   iXBRL 8-K 21426
  Complete submission text file 0001193125-22-066060.txt   142133

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA tptx-20220228.xsd EX-101.SCH 2877
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE tptx-20220228_lab.xml EX-101.LAB 17994
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tptx-20220228_pre.xml EX-101.PRE 11275
6 EXTRACTED XBRL INSTANCE DOCUMENT d278002d8k_htm.xml XML 3370
Mailing Address 10628 SCIENCE CENTER DRIVE, SUITE 200 SAN DIEGO CA 92121
Business Address 10628 SCIENCE CENTER DRIVE, SUITE 200 SAN DIEGO CA 92121 858-926-5251
Turning Point Therapeutics, Inc. (Filer) CIK: 0001595893 (see all company filings)

IRS No.: 463826166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38871 | Film No.: 22714058
SIC: 2834 Pharmaceutical Preparations